- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02002234
Hemicraniectomy for Malignant Middle Cerebral Artery Infarction (HeMMI) (HeMMI)
April 16, 2020 updated by: University of the Philippines
Hemicraniectomy for Malignant Middle Cerebral Artery Infarction (HeMMI): A Single Center Randomized Controlled Clinical Trial
A single-centered, randomized, controlled clinical trial comparing standardized medical care alone with standardized medical care and decompressive hemicraniectomy to determine the effectiveness of decompressive surgery more definitively in patients with clinical signs of infarction of the Middle Carotid Artery (MCA) territory.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
A single-centered, randomized, controlled clinical trial comparing standardized medical care alone with standardized medical care and decompressive hemicraniectomy to determine the effectiveness of decompressive surgery more definitively in patients with clinical signs of infarction of the MCA territory and and who arrived at the hospital within 72 hours of symptom onset.
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Metro Manila
-
Manila, Metro Manila, Philippines, 1000
- Philippine General Hospital - University of the Philippines Manila
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients between 18 to 65 years old who presented with clinical signs of infarction of the MCA territory and who arrived at the hospital within 72 hours of symptom onset. Other inclusion criteria included a Glasgow coma score (GCS) of 6 to14 in patients with right MCA infarction or GCS 5 to 9 in patients with left MCA infarction (adjusted to account for effect on speech deficit on GCS scores), or GCS of 15 on arrival but subsequently deteriorated neurologically as defined by a score of ≥1 on the level of consciousness item of the National Institutes of Health Stroke Scale (NIHSS);computed tomography (CT) scan of the head showing ischemic changes corresponding to more than 50% of the MCA territory with or without involvement of other vascular territories;and written informed consent from the patient or a legal representative.
Exclusion Criteria:
- Patients with previous disabling neurological disease, an estimated premorbid modified Rankin Scale (mRS) score >2; terminal illness; presence of serious medical comorbidities like end-stage renal failure and cardiac disease with severe hemodynamic compromise; infarction due to surgical complications or vasospasm; primary intracranial hemorrhage; coagulopathies; and high risk for surgery upon assessment by the medical team.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
OTHER: Medical Treatment Arm
Received standardized medical therapy in an intensive care unit (ICU), which included elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol.
Mean arterial pressure was maintained above 90 mm Hg.
Hemoglobin concentration was maintained at all times above 90 g/L.
Hyperglycemia, hyperthermia and hypotension were avoided or corrected when present.
|
Standard medical treatment involves elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol.
Mean arterial pressure was maintained above 90 mm Hg.
Hemoglobin concentration was maintained at all times above 90 g/L.
|
|
OTHER: Surgery with Medical Treatment Arm
Aside from receiving standardized medical therapy, decompressive hemicraniectomy was performed by removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa.
The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia.
The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.
Cranioplasty was performed during a separate admission on an elective basis not earlier than 6 months from the initial surgery.
|
Hemicraniotomy involves removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa.
The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia.
The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional status measured by modified Rankin Score (mRS)
Time Frame: up to six months
|
The primary outcome measure was functional status measured by the modified Rankin Score, dichotomized as a good status (mRS 0-3) or poor status (mRS 4-6).
A score of mRS 0-3 indicates functional status ranging from no symptoms to "moderate disability" (defined in the modified Rankin Scale as requiring some help, but able to walk without assistance); mRS 4-6 indicates functional status ranging from "moderately severe disability" (unable to walk or to attend to own bodily needs without assistance) through to death.
A cut off of mRS 3 was adopted a priori because the ability to walk independently, with or without the help of a device, was considered a favorable outcome.
Follow-up assessments, including mRS, were at seven days, two weeks, one month, three months, and six months post-stroke.
|
up to six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survival measured by modified Rankin Score (mRS)
Time Frame: up to six months
|
The Secondary outcome measure is the survival of the patients at six months measured using mRS scores dichotomized at mRS 0-4 and mRS 5-6 at six months.
A score of mRS 0-4 indicates functional status ranging from no symptoms to "moderately severe disability" (unable to walk without assistance and unable to attend to own bodily needs without assistance); mRS 5-6 indicates functional status ranging from "severe disability" (bedridden, incontinent and requiring constant nursing care and attention) through to death.
The latter outcome was considered because it was included in previous trial reports
|
up to six months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Annabelle E Chua, MD, University of the Philippines Manila
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2002
Primary Completion (ACTUAL)
December 1, 2009
Study Completion (ACTUAL)
December 1, 2009
Study Registration Dates
First Submitted
November 7, 2013
First Submitted That Met QC Criteria
November 29, 2013
First Posted (ESTIMATE)
December 5, 2013
Study Record Updates
Last Update Posted (ACTUAL)
April 20, 2020
Last Update Submitted That Met QC Criteria
April 16, 2020
Last Verified
February 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Brain Ischemia
- Stroke
- Brain Infarction
- Cerebral Arterial Diseases
- Intracranial Arterial Diseases
- Cerebral Infarction
- Infarction
- Infarction, Middle Cerebral Artery
Other Study ID Numbers
- RIDO 2002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infarction
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Beijing Northland Biotech. Co., Ltd.Not yet recruitingAcute Myocardial Infarction (AMI) | Acute Myocardial Infarction of Anterior Wall | Acute Myocardial Infarction With ST Elevation | Acute Myocardial Infarction With ST Segment Elevation | Acute Myocardial Infarction of Left VentricleChina
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SAWithdrawn
-
Samsung Medical CenterThe Korean Society of CardiologyNot yet recruiting
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationCompletedST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionUnited States, Spain, Netherlands, Canada, Australia, Serbia, Egypt, Switzerland, Hungary, United Kingdom, France, Czechia, Nepal, North Macedonia
-
Harbin Medical UniversityNot yet recruitingNon-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)Acute Myocardial Infarction (AMI) | ST-Segment Elevation Myocardial Infarction(STEMI) | Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)China
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
Clinical Trials on Standard medical treatment
-
Hospices Civils de LyonTerminatedAnal IncontinenceFrance
-
Xinqiao Hospital of ChongqingSuspendedVertebrobasilar StrokeChina
-
Xijing HospitalNot yet recruitingPulmonary Arterial Hypertension (PAH)
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingLiver Cirrhosis | Acute Kidney InjuryIndia
-
University Hospital, Basel, SwitzerlandCompleted
-
Institute of Liver and Biliary Sciences, IndiaRecruitingLiver Cirrhosis | Acute Kidney InjuryIndia
-
Al-Quds UniversityNot yet recruitingThe Effect of Psychosocial Support on Improving Breast Cancer Patients Response to Medical TreatmentBreast Cancer - FemalePalestinian Territories
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
The First Affiliated Hospital of University of...RecruitingAcute Ischemic Stroke | Endovascular ThrombectomyChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingCognitive Function | StenosisChina